Petrelintide, a human amylin analogue for the treatment of obesity (ZUPREME 1): a randomised, double-blind, placebo-controlled, phase 2 trial

The Lancet Diabetes & Endocrinology · Elsevier

Аннотация

Publication date: November 2026 Source: The Lancet Diabetes & Endocrinology, Volume 14, Issue 11 Author(s): W Timothy Garvey, Jamy Ard, Lisa Connery, Juan Pablo Frias, Carel W le Roux, Kirsi H Pietiläinen, Maj Dinesen, Berith F Hagen, Louise Larsen, Dan Hesse, David M Kendall

Читать у издателя →

Похожие статьи